CD8A and neoplasm: To further verify the contribution of CD8+ T cells to the enhanced antitumor efficacy of aPD-L1, we developed an in vivo CT26 mouse tumor model and utilized it for examining tumor responses following vehicle control, tucidinostat monotherapy ± CD8+ T cell depletion, and tucidinostat plus aPD-L1 combination therapy ± CD8+ T cell depletion.